Welcome to our dedicated page for Predictmedix news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on Predictmedix stock.
Predictmedix Inc. (PMEDF) delivers AI-driven health screening solutions for global safety challenges. This page provides investors and stakeholders with official news updates on technological advancements, strategic partnerships, and operational developments.
Access real-time updates on AI health screening innovations, including deployments in healthcare, aviation, and government sectors. Track announcements related to Safe Entry Stations, regulatory milestones, and financial performance.
Users can expect verified updates on multispectral imaging breakthroughs, government contract awards, and expansion into new markets. All content is sourced directly from company filings and authorized communications.
Bookmark this page for streamlined access to Predictmedix's evolving role in non-invasive health monitoring technology. Check regularly for developments impacting public health infrastructure and workplace safety standards.
Predictmedix AI (OTC: PMEDF) positions its Smart Health AI Stations as a strategic alternative following FDA's decision to phase out mandatory animal testing in drug development. The company's technology offers non-invasive, human-centric solutions for preclinical and clinical evaluations.
The AI-powered stations, which have conducted over 500,000 scans with up to 95% accuracy in vital sign detection, monitor various health indicators including vitals, impairment, fatigue, and infection markers. The technology provides real-time physiological and cognitive assessment through advanced algorithms.
The platform analyzes human biomarkers to predict physiological responses, offering direct human-relevant data instead of relying on animal models. Key features include AI-driven real-time assessments, scalable deployment options, contactless monitoring, and compliance with data privacy standards.
Predictmedix AI (CSE: PMED, OTC: PMEDF) has achieved a significant milestone with its Smart Health AI Stations completing over 500,000 individual scans. The company's non-invasive, AI-powered screening tools integrate advanced computer vision with adaptive machine learning to detect health risks including infectious disease symptoms, mental health indicators, and impairment in real-time.
The technology offers privacy-focused health insights and features rapid vitals screening and impairment detection capabilities. Dr. Rahul Kushwah, Chief Operating Officer, emphasized that the milestone demonstrates the trust earned and lives protected through their solution. The system's algorithms improve with each scan, enabling faster and more reliable interventions.
The company's Smart Health AI Stations are designed for deployment across healthcare, corporate, and public sectors, with expanding capabilities in mental health assessment, including detection of stress and fatigue. Predictmedix AI plans to strengthen industry partnerships and explore new opportunities in telemedicine and personalized analytics.
Predictmedix AI (CSE: PMED, OTC: PMEDF) has successfully closed the third and final tranche of its non-brokered private placement, raising $100,000 CAD. The placement saw strong insider participation, with $90,000 subscribed by insiders Sheldon Kales and Dr. Rahul Kushwah ($45,000 each).
The company issued 5,000,000 units at $0.02 per unit, with each unit comprising one common share and one purchase warrant. Warrants are exercisable at $0.05 per share for 24 months, with an acceleration clause if share prices exceed $0.10 for ten consecutive trading days.
Additionally, Predictmedix has begun fabrication of fifteen Smart Health AI Stations for strategic deployment, primarily targeting the United States market. The proceeds will support market expansion, with a focus on U.S. enterprise and government sectors.
Predictmedix AI (CSE: PMED, OTC: PMEDF) has successfully closed the second tranche of its non-brokered private placement, raising $405,500 with significant participation from two German family offices. The company issued 20,275,000 units at $0.02 per unit.
Each unit comprises one common share and one purchase warrant, allowing holders to acquire an additional common share at $0.05 within 24 months. The company maintains the right to accelerate the warrant expiry if the stock's volume-weighted average trading price exceeds $0.10 for ten consecutive trading days on the CSE.
The securities issued are subject to a four-month and one-day statutory hold period, with a third and final tranche expected to close shortly.
Predictmedix AI (OTC: PMEDF) has announced the launch of enhanced Smart Health AI Stations across the United States, partnering with Manchester Marketing Group Inc. The initiative targets the rapidly growing population health management market, currently valued at USD 32.94 billion with projected growth to USD 126.16 billion by 2032.
The Smart Health AI Stations provide non-contact health screenings using AI technology for real-time vitals monitoring and substance-induced impairment detection. Ten units are being considered for demonstration to corporate and government entities across the USA. The technology will be showcased through partnerships extending to Pakistan, Dubai, and Sub-Saharan Africa.
The stations offer applications in workplace wellness, healthcare screening, public safety, education, and government sectors, providing real-time health assessments and data-driven wellness insights.
Predictmedix AI (CSE: PMED) (OTC: PMEDF) has successfully closed the first tranche of its non-brokered private placement, raising $320,000 through the issuance of 16,000,000 units at $0.02 per unit. Each unit comprises one common share and one purchase warrant, exercisable at $0.05 per share for 24 months.
The warrant expiry date may be accelerated if the company's shares trade at $0.10 or higher for ten consecutive trading days on the CSE, with a minimum 30-day notice to holders. The proceeds will be used to expand U.S. market opportunities for Predictmedix's AI-driven health management solutions in enterprise and government sectors.
Additionally, the company granted 2,000,000 stock options to a consultant, exercisable at $0.05 per share with a one-year term. All securities issued are subject to a four-month and one-day statutory hold period.
Predictmedix AI (PMEDF) announced a strategic repositioning, shifting its focus from traditional healthcare to AI-powered health management technologies. The company is developing solutions for workplace safety, workforce readiness, and public sector health screening.
The company's AI-driven solutions aim to help businesses assess workforce readiness through detection of fatigue, vital signs monitoring, and substance impairment screening. These technologies are designed to integrate with HR, compliance, and safety protocols in industries such as manufacturing, logistics, energy, construction, and defense.
Additionally, Predictmedix AI is exploring opportunities in defense, public safety, and education sectors, focusing on workplace health monitoring applications and AI-driven assessments for law enforcement and military personnel.
Predictmedix AI (CSE: PMED) (OTC: PMEDF) has announced a non-brokered private placement offering of up to 50,000,000 units at C$0.02 per unit, aiming to raise up to C$1,000,000. Each unit consists of one common share and one warrant, with each warrant allowing the purchase of one common share at C$0.05 within 24 months of closing.
The company has begun receiving commitments for the placement, according to COO Dr. Rahul Kushwah. The proceeds will be allocated to general working capital and expanding market opportunities in the U.S. for AI-powered health management solutions across enterprise and government sectors. All securities issued will have a four-month and one-day statutory hold period.
FAQ
What is the current stock price of Predictmedix (PMEDF)?
What is the market cap of Predictmedix (PMEDF)?
